Progression of Atherosclerosis as Assessed by Carotid Intima-Media Thickness in Patients with HIV Infection

Circulation

Volumn 109, Issue 13, 2004, Pages 1603-1608

  Hsue, Y ^b   Lo, Joan C ^b   Franklin, Arlana ^b   Bolger, Ann F ^b   Martin, Jeffrey N ^b   Deeks, Steven G ^b   Waters, David D ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Atherosclerosis; Carotid arteries; Risk factors

Indexed keywords

AUTACOID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR;

ADULT; AGE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNE DEFICIENCY; LIPID BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SMOKING; UNITED STATES;

ADULT; BIOLOGICAL MARKERS; CALIFORNIA; CAROTID ARTERY DISEASES; CAROTID STENOSIS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CORONARY ARTERY BYPASS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; HYPERTENSION; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; SMOKING; TUNICA INTIMA; TUNICA MEDIA;

EID: 1842474732     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000124480.32233.8A     Document Type: Article

References (45)

1. Website of the National Institute of Allergy and Infectious Disease-National Institutes of Health. Available at: http://www.niaid.gov/factsheets/aidsstat.htm. Accessed March 3, 2004.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
4. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
5. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
6. Meng Q, Lima JA, Lai H, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J. 2002;144:642-648.
7. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328.
8. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747-1748.
9. DAD Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1991-2003.
10. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74:1399-1406.
11. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997;146:483-494.
12. Bots ML, Hoes AW, Koudstaal P, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997;96:1432-1437.
13. O'Leary DH, Polak JF, Kronmal RA, et al. for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14-22.
14. Espeland MA, Craven TA, Riley WA, et al. Reliability of longitudinal ultrasonic measurements of carotid intima-medial thickness. Stroke. 1996;27:480-485.
15. Furberg CD, Adams HP Jr, Applegate WB, et al. for the Asymptomatic Carotid Artery Progression (ACAPS) Study Research Group. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
16. Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: association with cardiovascular risk factors in the ARIC Study. Am J Epidemiol. 1991;134:250-256.
17. Wu KK, Folsom AR, Heiss G, et al, for the ARIC Study Investigators. Association of coagulation factors and inhibitors with carotid artery atherosclerosis: early results of the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 1992;2:471-480.
18. Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-media thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke. 1993;24:1297-1304.
19. Aminbakhsh A, Mancini GBJ. Carotid intima-media thickness measurements: what defines an abnormality? A systematic review. Clin Invest Med. 1999;22:149-157.
20. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
21. Zangerle R, Sarcletti M, Gallati H, et al. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr. 1994;11:1149-1156.
22. Freeman DJ, Griffin BA, Murphy E, et al. Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur J Clin Invest. 1993;23:630-640.
23. Segerer S, Bogner JR, Walli R, et al. Hyperlipidemia under treatment with protease inhibitors. Infection. 1999;27:77-81.
24. Périard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999;100:700-705.
25. Mulligan K, Grunfeld C, Tai WW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
26. Walli R, Herfort O, Michi GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:FI67-F163.
27. Chambless LE, Folsom AR, Davis V, et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis in Communities Study, 1987-1998. Am J Epidemiol. 2002;155:38-47.
28. Whisnant JP, Homer D, Ingall TJ, et al. Duration of cigarette smoking is the strongest predictor of severe extracranial carotid artery atherosclerosis. Stroke. 1990;21:707-714.
29. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 2000;95:249-255.
30. Liu Z, Cumberland WG, Hultin LE, et al. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:332-340.
31. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999;5:83-89.
32. Lederman MM, Kalish LA, Asmuth D, et al. "Modeling" relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses. AIDS. 2000;14:951-958.
33. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS. 2002;16:1859-1866.
34. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543.
35. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
36. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
37. Hansson GK, Jonasson L, Lojsthed B, et al. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis. 1988;72:135-141.
38. Zhou X, Nicoletti A, Elhage R, et al. Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000;102:2919-2922.
39. Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Thl) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33-43.
40. Salomon RN, Hughes CC, Schoen FJ, et al. Human coronary transplantation-associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol. 1991;138:791-798.
41. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 2000;14:123-128.
42. Depairon M, Chessex S, Sudre P, et al. with the Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS. 2001;15:329-334.
43. Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis. 2002;162:433-438.
44. Chironi G, Escaut L, Gariepy J, et al. Carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr. 2003;32:490-493.
45. Mercie P, Thiébaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med. 2002;34:55-63.